Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,737
  • Shares Outstanding, K 96,265
  • Annual Sales, $ 0 K
  • Annual Income, $ -115,860 K
  • EBIT $ -163 M
  • EBITDA $ -160 M
  • 60-Month Beta 3.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 270.80% (+9.51%)
  • Historical Volatility 144.22%
  • IV Percentile 92%
  • IV Rank 30.99%
  • IV High 687.57% on 04/08/25
  • IV Low 83.65% on 07/23/25
  • Expected Move (DTE 9) 0.27 (10.88%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 216
  • Volume Avg (30-Day) 1,808
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 56,187
  • Open Int (30-Day) 65,182
  • Expected Range 2.23 to 2.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.42
  • Low Estimate -0.46
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +32.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.01 +24.38%
on 11/21/25
2.70 -7.41%
on 12/05/25
-0.05 (-1.96%)
since 11/07/25
3-Month
1.65 +51.06%
on 09/10/25
3.67 -31.88%
on 10/31/25
+0.86 (+52.44%)
since 09/09/25
52-Week
0.99 +152.53%
on 04/07/25
3.67 -31.88%
on 10/31/25
-0.61 (-19.61%)
since 12/09/24

Most Recent Stories

More News
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient...

CABA : 2.50 (+0.81%)
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...

CABA : 2.50 (+0.81%)
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses...

CABA : 2.50 (+0.81%)
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cabaletta Bio (CABA – Research Report) and Icon (ICLR – Research Report) with bullish sentiments.Elevate...

CABA : 2.50 (+0.81%)
ICLR : 181.29 (-0.44%)
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE)...

CABA : 2.50 (+0.81%)
Cantor Fitzgerald Reaffirms Their Buy Rating on Cabaletta Bio (CABA)

Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Cabaletta Bio today and set a price target of $15.00. The company’s shares opened today at $3.15.Elevate Your Investing Strategy:...

CABA : 2.50 (+0.81%)
Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silence Therapeutics (SLN – Research Report) and Cabaletta Bio (CABA – Research Report) with bullish...

CABA : 2.50 (+0.81%)
SLN : 6.20 (-10.27%)
William Blair Sticks to Their Buy Rating for Cabaletta Bio (CABA)

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Cabaletta Bio. The company’s shares closed yesterday at $2.85.Elevate Your Investing Strategy: Take advantage of...

CABA : 2.50 (+0.81%)
Cabaletta Bio Presents Promising RESET-PV Trial Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta...

CABA : 2.50 (+0.81%)
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators...

CABA : 2.50 (+0.81%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 2.64
2nd Resistance Point 2.59
1st Resistance Point 2.55
Last Price 2.50
1st Support Level 2.45
2nd Support Level 2.40
3rd Support Level 2.36

See More

52-Week High 3.67
Fibonacci 61.8% 2.65
Last Price 2.50
Fibonacci 50% 2.33
Fibonacci 38.2% 2.01
52-Week Low 0.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar